Beckman Coulter’s Alzheimer’s Blood Test Receives FDA Breakthrough Device Designation

ANGLE Announces Breakthrough Dual CTC-DNA and ctDNA Analysis with Illumina’s NGS Solution

Diatech Pharmacogenetics and Merck Expand Collaboration to Enhance RAS Biomarker Testing in MEA Region

DCG Unveils AI-Powered Video-Reporting for Personalized Chemotherapy Selection

FDA Approves Monthly Maintenance Dosing for LEQEMBI® in Alzheimer’s Treatment

FDA Approves Enhertu for HR-Positive, HER2-Low and HER2-Ultralow Metastatic Breast Cancer

CrisprBits Unveils State-of-the-Art CRISPR Gene Editing Lab in Bengaluru

Takara Bio Acquires Curio Bioscience, Advancing Leadership in Spatial Genomics

Tempus AI Launches FDA-Approved xT CDx for Comprehensive Solid Tumor Profiling

FDA Accepts Eisai’s Biologics License Application for LEQEMBI® Subcutaneous Autoinjector for Alzheimer’s Disease

Paige’s FullFocus™ Digital Pathology Viewer Receives FDA 510(k) Clearance for Expanded Compatibility

Grifols, MJFF Launch Chronos-PD to Identify Early Parkinson’s Biomarkers

Gates Foundation Invests $50M in Tessera’s In Vivo Gene-Editing Therapy for Sickle Cell Disease

GSK Acquires IDRx for $1 Billion to Advance Precision Therapy for GIST

Scipher Medicine and Roivant Partner to Advance Precision Medicine in Rheumatology

Home
/
update
/
details

ANGLE Announces Breakthrough Dual CTC-DNA and ctDNA Analysis with Illumina’s NGS Solution

NextEdge Admin

30 Jan 2025

2 min 49 sec

ANGLE plc , a global leader in liquid biopsy solutions, has announced successful results for its dual circulating tumor DNA (ctDNA) and circulating tumor cell (CTC-DNA) workflow using an end-to-end Illumina sequencing solution.

Over the past six months, ANGLE has resolved technical challenges to integrate Illumina assays and next-generation sequencing (NGS) for a complete dual-analysis solution. In a study involving 27 lung cancer patients, CTCs were harvested using the Parsortix® system, and ctDNA was isolated from plasma. Both were analyzed using Illumina's 79-gene lung cancer panel on the NextSeq 2000 platform.

The findings highlight the importance of CTC-DNA analysis alongside ctDNA. In untreated patients (n=8), 100% had cancer mutations found only in CTC-DNA, while 90% of treated patients (n=19) had unique CTC-DNA mutations not detected in ctDNA. Dual analysis revealed twice as many mutations, enhancing biomarker discovery for personalized treatment.

Due to these significant findings, Illumina has dedicated its European Association for Cancer Research (EACR) webinar to ANGLE’s research. The webinar, titled Complementary Insights: Exploring the Dual Analysis of Circulating Tumor Cells and Circulating DNA, will take place on February 6, 2025, at 16:00 GMT.

ANGLE aims to align the Parsortix system with Illumina’s NGS instruments and gene panels, enabling broader use of CTC analysis in NGS workflows. Unlike ctDNA, CTCs provide intact cancer cells, facilitating multiomics research, including RNA and protein sequencing. This minimally invasive liquid biopsy approach allows repeatable sampling, offering deeper cancer insights.

Chief Scientific Officer Karen Miller emphasized the potential for dual analysis to enhance liquid biopsy research and clinical drug development. CEO Andrew Newland expressed excitement about collaborating with Illumina and presenting these breakthrough findings at the upcoming webinar.